DeepCDR Biologics offers technologies and services for characterizing and engineering antibody therapeutics. Their platform provides scalable solutions for antibody discovery and development.
Funding
$42M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MCFounders
Product
Problem
Developing effective antibody therapeutics is often hindered by the limitations of traditional discovery methods, which struggle to address complex targets and optimize drug-like properties early in the development process. This can lead to delays, increased costs, and a higher risk of failure in clinical trials.
Solution
DeepCDR Biologics, an Alloy Therapeutics company, provides integrated platforms and services to accelerate the discovery and development of antibody therapeutics. They offer a suite of technologies, including transgenic mouse platforms for fully human antibody discovery, AI/ML-powered clone selection, and advanced antibody optimization workflows. Their end-to-end services cover monoclonal and bispecific antibody discovery, format engineering, and functional screening, enabling partners to efficiently generate high-quality therapeutic candidates. DeepCDR's approach streamlines the path to IND by addressing developability challenges early on and providing access to cutting-edge tools and expertise.
Target Audience
The primary target audience includes pharmaceutical and biotechnology companies, as well as academic research institutions, involved in the discovery and development of antibody therapeutics, TCR mimics, genetic medicines, and cell therapies.
Features
- ATX-GX™ transgenic mouse platforms for in vivo human antibody discovery, offering strain diversity and flexible licensing terms.
- Monoclonal antibody discovery services leveraging humanized transgenic mice, optimized immunization strategies, and AI/ML-powered clone selection.
- Bispecific antibody discovery services providing a fully integrated workflow from drug concept to lead, including format engineering and functional screening.
- Antibody optimization services employing AI/ML-powered in silico design, high-throughput expression and testing, and advanced display platforms.
- Keyway™ TCR mimic antibody discovery platform for targeting intracellular peptides presented on MHC complexes.
- AntiClastic™ antisense oligonucleotide (ASO) platform for genetic medicines, featuring a transiently cyclized structure for improved potency and safety.
- iCAR-T platform for cell therapies, offering a versatile T cell platform with enhanced safety, potency, and scalability.